TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02849457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Early Vigabatrin
Description: Subjects randomized to vigabatrin will be treated with vigabatrin 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Vigabatrin
Description: Subjects randomized to vigabatrin will be treated with vigabatrin 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Vigabatrin (Placebo)
Description: Subjects randomized to placebo will be treated with matching placebo at 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
Study: NCT03818581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant
Description: 10-mg or 20-mg Suvorexant capsules
Study: NCT00430365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: oral drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo
Study: NCT02919332

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo 18F-FDG PET/CT

Intervention type: RADIATION
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo 18F-FDG PET/CT
Study: NCT01060956

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reporting of two different bacteria in urine culture
Description: reporting of two different bacteria in urine culture

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: reporting mixed growth on urine culture
Description: reporting mixed growth on urine culture
Study: NCT03930433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diltiazem
Description: Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebivolol+Diltiazem
Description: Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
Study: NCT04569370

Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: Surgical removal of Gall bladder using laparoscopy

Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: Surgical removal of Gall bladder using laparoscopy
Study: NCT03969420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib (flavopiridol) and cytarabine (Ara-C)
Description: Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib (flavopiridol) and cytarabine (Ara-C)
Description: Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib (flavopiridol)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib (flavopiridol)
Description: Administered intravenously
Study: NCT03996213

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: head down position
Description: Head-down position will be achieved by 30 degrees tilting of the whole operating table 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: leg elevation position
Description: Leg elevation position will be achieved by raising the patient legs for 30 cm using two standard pillows positioned under the heels 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
Study: NCT00335075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semustine
Description: Semustine orally once every 28 days at a dose of 150 mg/m2/day.
Study: NCT00331487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
Study: NCT01741818

Intervention type: OTHER
Intervention: Measuring IVC collapsibility index by bedside ultrasonography
Study: NCT02596672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The friendly walking group
Description: A 12 week peer led walking group for adults and older adults (\> 55 years) living in independent living communities in Northern Ireland. Designed to increase physical activity levels of inactive older adults and measure sustained changes in physical behaviour 6 months after the intervention ends.
Study: NCT02547935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Tablets administered orally once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg
Description: Tablets administered orally once daily for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Description: Tablets administered orally once daily for 24 weeks.
Study: NCT03735342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio Recording
Description: All participants will be provided with a re-playable audio recording of the discharge discussion on a portable electronic device. In addition, participants will have the option to record the discharge discussion on a personally-owned smartphone or receive access to the recording online, via the Open Recording Automated Logging System (ORALS).
Study: NCT02858258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP/R-DHAP
Description: Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP/R-DHAP
Description: Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP/R-DHAP
Description: Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Induction)
Description: Ibrutinib: only in cycle 1,3,5 on Day 1-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Induction)
Description: Ibrutinib: only in cycle 1,3,5 on Day 1-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASCT conditioning
Description: ASCT conditioning THAM or BEAM, stratified per site before trial activation at site~THAM (TBI (total body irradiation), Ara-C, Melphalan) or~BEAM (BCNU, Etoposide, Cytarabine, Melphalan)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASCT conditioning
Description: ASCT conditioning THAM or BEAM, stratified per site before trial activation at site~THAM (TBI (total body irradiation), Ara-C, Melphalan) or~BEAM (BCNU, Etoposide, Cytarabine, Melphalan)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Maintenance)
Description: Ibrutinib (Maintenance), daily 560 mg for 2 years;
Study: NCT02951299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400Mg Tablet
Description: Investigators with AKI will received oral pentoxifylline (400 mg) three times a day for 14 days or no pentoxifylline according to their decision.
Study: NCT02858258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Maintenance)
Description: Ibrutinib (Maintenance), daily 560 mg for 2 years;
Study: NCT01767285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel implant
Description: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel implant
Description: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.
Study: NCT01095770

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF Ablation with Ablation Frontiers Technology
Description: AF Ablation with Ablation Frontiers Technology - PVAC, TVAC and MASC.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF Ablation with LASSO catheter
Description: AF Ablation with traditional LASSO catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reveal XT
Description: Reveal XT implantable loop recorder monitored group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent Dual Chamber Pacemaker
Description: This group will be monitored with a dual chamber pacemaker with advanced AF monitoring capabilities.
Study: NCT03948425

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: spectral CT
Description: Head spectral CT
Study: NCT01727154

Intervention type: BIOLOGICAL
Intervention: Sipuleucel-T
Description: Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
Study: NCT03237663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The oral O1 / O139 cholera vaccine (enteric capsules)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The oral O1 / O139 cholera vaccine (enteric capsules)
Study: NCT04705753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cretan IAMA
Description: Cretan IAMA (CAPeo) soft gels, 1 ml/day of a 1.5% essential oil combination from three aromatic plants (Thymbra 59 capitata (L.) Cav., Origanum dictamnus L., Salvia fruticosa Mill.) in extra virgin olive oil
Study: NCT03622840

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Remediation
Description: Weekly 30-45mins Cognitive Remediation Sessions over 11 weeks
Study: NCT00441896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01101048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 167
Description: Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
Study: NCT02927483

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Endolex Forte®
Description: Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A combination of diosmin and hesperidin
Description: A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
Study: NCT01852136

Intervention type: DEVICE
Intervention: BD NEXT 31G x 5 mm pen needle
Description: Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.

Intervention type: DEVICE
Intervention: BD NEXT 31G x 8mm pen needle
Description: Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.

Intervention type: DEVICE
Intervention: BD NEXT 32G x 4mm pen needle
Description: Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
Study: NCT02290093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard full-volume PEG
Description: Subjects will be asked to take 4L of PEG-3350 solution the day prior to procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Split-dose full-volume PEG
Description: Subjects will be asked to take 2L of PEG-3350 solution the day prior to procedure, followed by another 2L of PEG-3350 solution on the day of the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Split-dose low-volume PEG
Description: Subjects will be asked to take 1L of PEG-3350 containing ascorbic acid solution the day prior to procedure, followed by another 1L of PEG-3350 containing ascorbic acid solution on the day of the procedure.
Study: NCT01365572

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xiene V stent, Endeavor Resolute stent
Description: for each lesion, randomized either Xience V stent or Endeavor Resolute stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xiene V stent, Endeavor Resolute stent
Description: for each lesion, randomized either Xience V stent or Endeavor Resolute stent
Study: NCT00727064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine Succinate Sustained-Release (DVS SR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine Succinate Sustained-Release (DVS SR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine Extended Release (VEN ER)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine Extended Release (VEN ER)
Study: NCT04073407

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AXA1957
Description: Amino acids, food study

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04524923

Intervention type: OTHER
Intervention: visual motor integration
Description: investigate the relation between touch screen usage and visual motor integration in preschoolers

Intervention type: OTHER
Intervention: Quality of life assessment
Description: investigate the relation between touch screen usage and Quality of life assessment in preschoolers

Intervention type: OTHER
Intervention: Cognitive Functioning
Description: investigate the relation between touch screen usage and Cognitive Functioning assessment in preschoolers
Study: NCT00479232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Study: NCT01680172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single dose (0.5 mg/kg) of liquid ketamine 10mg/mL solution taken by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of liquid placebo solution taken by mouth
Study: NCT02408822

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA Balloon dilatation catheter Advance® (Cook® Medical)
Description: 2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting PTA Balloon dilatation catheter Advance® 18 PTX®
Description: 2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
Study: NCT02109224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02505061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital-based Program
Description: The research team will discuss with the clinical therapists who will provide training program in a hospital for 120 minutes/per session, 2 sessions/per week for a total of 9-week intervention. In addition, the research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase. The treatment program of the two sessions will be preplanned and adjusted by the occupational therapist through clinical observation of participant's performance in the previous session. Training will still concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person), and upper limb use in functional tasks with driving in a hospital,discussed by the family, the treating therapist and the research team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Therapy Program
Description: The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase
Study: NCT01562691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasopore
Description: Bilateral nasal packing using Nasopore without airway integrated

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: airway integrated Nasopore
Description: post nasoseptoplasty with nasal packing using airway integrated Nasopore

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: airway-integrated Vaseline gauze
Description: post nasal septoplasty with packing using airway-integrated Vaseline gauze
Study: NCT03541642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Description: Targeted PrEP counseling; targeted written/visual materials; follow up supportive text messages; distribution of PrEP at the syringe exchange

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Intervention
Description: General messaging from medical personnel; reminder text messages; distribution of PrEP at the syringe exchange
Study: NCT04455334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Error-augmented treadmill training
Description: walk on split-belt treadmill
Study: NCT04624243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone administered QD at a dose of 6 mg via oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-8189
Description: MK-8189-matching placebo administered QD via oral tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-8189
Description: MK-8189-matching placebo administered QD via oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to risperidone
Description: Risperidone-matching placebo administered QD via oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to risperidone
Description: Risperidone-matching placebo administered QD via oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to risperidone
Description: Risperidone-matching placebo administered QD via oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to risperidone
Description: Risperidone-matching placebo administered QD via oral capsule.
Study: NCT02520973

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sputum sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sputum sample
Study: NCT01022580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infasurf surfactant (ONY, Inc.)
Description: Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: Late doses of Sham (No treatment) will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
Study: NCT02314884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cafusertib Hydrochloride
Study: NCT00890162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab (Xolair)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos